Cargando…
Cancer immunotherapy trials: leading a paradigm shift in drug development
| Autores principales: | , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2016
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4949883/ https://www.ncbi.nlm.nih.gov/pubmed/27437105 http://dx.doi.org/10.1186/s40425-016-0146-9 |
| _version_ | 1782443496847704064 |
|---|---|
| author | Emens, Leisha A. Butterfield, Lisa H. Hodi, F. Stephen Marincola, Francesco M. Kaufman, Howard L. |
| author_facet | Emens, Leisha A. Butterfield, Lisa H. Hodi, F. Stephen Marincola, Francesco M. Kaufman, Howard L. |
| author_sort | Emens, Leisha A. |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-4949883 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2016 |
| publisher | BioMed Central |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-49498832016-07-20 Cancer immunotherapy trials: leading a paradigm shift in drug development Emens, Leisha A. Butterfield, Lisa H. Hodi, F. Stephen Marincola, Francesco M. Kaufman, Howard L. J Immunother Cancer Commentary BioMed Central 2016-07-19 /pmc/articles/PMC4949883/ /pubmed/27437105 http://dx.doi.org/10.1186/s40425-016-0146-9 Text en © The Author(s). 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
| spellingShingle | Commentary Emens, Leisha A. Butterfield, Lisa H. Hodi, F. Stephen Marincola, Francesco M. Kaufman, Howard L. Cancer immunotherapy trials: leading a paradigm shift in drug development |
| title | Cancer immunotherapy trials: leading a paradigm shift in drug development |
| title_full | Cancer immunotherapy trials: leading a paradigm shift in drug development |
| title_fullStr | Cancer immunotherapy trials: leading a paradigm shift in drug development |
| title_full_unstemmed | Cancer immunotherapy trials: leading a paradigm shift in drug development |
| title_short | Cancer immunotherapy trials: leading a paradigm shift in drug development |
| title_sort | cancer immunotherapy trials: leading a paradigm shift in drug development |
| topic | Commentary |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4949883/ https://www.ncbi.nlm.nih.gov/pubmed/27437105 http://dx.doi.org/10.1186/s40425-016-0146-9 |
| work_keys_str_mv | AT emensleishaa cancerimmunotherapytrialsleadingaparadigmshiftindrugdevelopment AT butterfieldlisah cancerimmunotherapytrialsleadingaparadigmshiftindrugdevelopment AT hodifstephen cancerimmunotherapytrialsleadingaparadigmshiftindrugdevelopment AT marincolafrancescom cancerimmunotherapytrialsleadingaparadigmshiftindrugdevelopment AT kaufmanhowardl cancerimmunotherapytrialsleadingaparadigmshiftindrugdevelopment |